Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Burkitt Lymphoma 24Prostatic Neoplasms 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Lymphoma, Large B-Cell, Diffuse 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10Leukemia, Biphenotypic, Acute 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, B-Cell 4Lymphoma 4Plasmablastic Lymphoma 3Lymphoma, T-Cell 3Lymphoma, Follicular 3Immunoblastic Lymphadenopathy 3Enteropathy-Associated T-Cell Lymphoma 3Melanoma 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Hodgkin Disease 2Down Syndrome 2Carcinoma, Merkel Cell 2Carcinoma, Basal Cell 2Blast Crisis 2Vasculitis, Central Nervous System 1Urogenital Neoplasms 1Subcutaneous panniculitis-like T-cell lymphoma 1Stiff-Person Syndrome 1Stage II Prostate Adenocarcinoma 1Rasmussen subacute encephalitis 1Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1Oropharyngeal Neoplasms 1

Interventions

Nivolumab 2prednylidene 1peginterferon alfa-2b 1dolutegravir 1deltacortene 1Zidovudine 1Vincristine 1Valproic Acid 1Tenofovir 1Specimen Handling 1Prednisone 1Pharmacogenomic Testing 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Interferon alpha-2 1Etoposide 1Doxorubicin 1Daclizumab 1Cyclophosphamide 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HTLV-I Infections × prednylidene × Clear all
NCT04301076 2026-05-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡